Ray Dalio Akero Therapeutics, Inc. Transaction History
Bridgewater Associates, LP
- $23.8 Billion
- Q3 2025
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 4,256 shares of AKRO stock, worth $230,675. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,256Holding current value
$230,675% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
91.4MCall Options Held
1.04MPut Options Held
372K-
Janus Henderson Group PLC London, X06.28MShares$340 Million0.14% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million9.63% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million3.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$245 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...